Activation of latent HIV using drug-loaded nanoparticles

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Kovochich, Michael ^a   Marsden, Matthew D ^b   Zack, Jerome A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRYOSTATIN 2; BUTYRIC ACID; NANOPARTICLE; NELFINAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BRYOSTATIN; DRUG CARRIER; LIPID; PROTEINASE INHIBITOR;

ANIMAL EXPERIMENT; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG POTENTIATION; EX VIVO STUDY; FETUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IN VITRO STUDY; LATENT VIRUS INFECTION; MOUSE; NONHUMAN; T LYMPHOCYTE ACTIVATION; VIRUS ACTIVATION; VIRUS INHIBITION; ANIMAL; CHEMISTRY; DRUG EFFECT; FEASIBILITY STUDY; HELA CELL; METABOLISM; PHYSIOLOGY; TRANSPORT AT THE CELLULAR LEVEL; VIROLOGY; VIRUS LATENCY;

ANIMALS; ANTI-HIV AGENTS; BIOLOGICAL TRANSPORT; BRYOSTATINS; CD4-POSITIVE T-LYMPHOCYTES; DRUG CARRIERS; FEASIBILITY STUDIES; HELA CELLS; HIV; HUMANS; LIPIDS; MICE; NANOPARTICLES; PROTEASE INHIBITORS; VIRUS ACTIVATION; VIRUS LATENCY;

EID: 79953689313     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018270     Document Type: Article

References (49)

1. Chun TW, Engel D, Mizell SB, Hallahan CW, Fischette M, et al. (1999) Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat Med 5: 651-655.
2. Lehrman G, Hogue IB, Palmer S, Jennings C, Spina CA, et al. (2005) Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 366: 549-555.
3. Lindkvist A, Eden A, Norstrom MM, Gonzalez VD, Nilsson S, et al. (2009) Reduction of the HIV-1 reservoir in resting CD4+ T-lymphocytes by high dosage intravenous immunoglobulin treatment: a proof-of-concept study. AIDS Res Ther 6: 15.
4. Prins JM, Jurriaans S, van Praag RM, Blaak H, van Rij R, et al. (1999) Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy. Aids 13: 2405-2410.
5. Folks TM, Justement J, Kinter A, Dinarello CA, Fauci AS, (1987) Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. Science 238: 800-802.
6. Laughlin MA, Zeichner S, Kolson D, Alwine JC, Seshamma T, et al. (1993) Sodium butyrate treatment of cells latently infected with HIV-1 results in the expression of unspliced viral RNA. Virology 196: 496-505.
7. Scripture-Adams DD, Brooks DG, Korin YD, Zack JA, (2002) Interleukin-7 induces expression of latent human immunodeficiency virus type 1 with minimal effects on T-cell phenotype. J Virol 76: 13077-13082.
8. van Praag RM, Prins JM, Roos MT, Schellekens PT, Ten Berge IJ, et al. (2001) OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD4+ T cell depletion. J Clin Immunol 21: 218-226.
9. Qatsha KA, Rudolph C, Marme D, Schachtele C, May WS, (1993) Go 6976, a selective inhibitor of protein kinase C, is a potent antagonist of human immunodeficiency virus 1 induction from latent/low-level-producing reservoir cells in vitro. Proc Natl Acad Sci U S A 90: 4674-4678.
10. Perez M, de Vinuesa AG, Sanchez-Duffhues G, Marquez N, Bellido ML, et al. Bryostatin-1 Synergizes with Histone Deacetylase Inhibitors to Reactivate HIV-1 from Latency. Curr HIV Res.
11. Mehla R, Bivalkar-Mehla S, Zhang R, Handy I, Albrecht H, et al. (1160) Bryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a receptor independent manner. PLoS One 5: e11160.
12. Vlach J, Pitha PM, (1992) Activation of human immunodeficiency virus type 1 provirus in T-cells and macrophages is associated with induction of inducer-specific NF-kappa B binding proteins. Virology 187: 63-72.
13. Mutter R, Wills M, (2000) Chemistry and clinical biology of the bryostatins. Bioorg Med Chem 8: 1841-1860.
14. Propper DJ, Macaulay V, O'Byrne KJ, Braybrooke JP, Wilner SM, et al. (1998) A phase II study of bryostatin 1 in metastatic malignant melanoma. Br J Cancer 78: 1337-1341.
15. Varterasian ML, Mohammad RM, Shurafa MS, Hulburd K, Pemberton PA, et al. (2000) Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Clin Cancer Res 6: 825-828.
16. Varterasian ML, Mohammad RM, Eilender DS, Hulburd K, Rodriguez DH, et al. (1998) Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia. J Clin Oncol 16: 56-62.
17. Varterasian ML, Pemberton PA, Hulburd K, Rodriguez DH, Murgo A, et al. (2001) Phase II study of bryostatin 1 in patients with relapsed multiple myeloma. Invest New Drugs 19: 245-247.
18. Mohammad RM, Katato K, Almatchy VP, Wall N, Liu KZ, et al. (1998) Sequential treatment of human chronic lymphocytic leukemia with bryostatin 1 followed by 2-chlorodeoxyadenosine: preclinical studies. Clin Cancer Res 4: 445-453.
19. Farokhzad OC, Langer R, (2009) Impact of nanotechnology on drug delivery. ACS Nano 3: 16-20.
20. Petros RA, DeSimone JM, Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov 9: 615-627.
21. Davis ME, Chen ZG, Shin DM, (2008) Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 7: 771-782.
22. Wagner V, Dullaart A, Bock AK, Zweck A, (2006) The emerging nanomedicine landscape. Nat Biotechnol 24: 1211-1217.
23. Torchilin VP, (2005) Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 4: 145-160.
24. Levchenko TS, Rammohan R, Lukyanov AN, Whiteman KR, Torchilin VP, (2002) Liposome clearance in mice: the effect of a separate and combined presence of surface charge and polymer coating. Int J Pharm 240: 95-102.
25. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, et al. (2008) Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther 83: 761-769.
26. Gabizon A, Isacson R, Libson E, Kaufman B, Uziely B, et al. (1994) Clinical studies of liposome-encapsulated doxorubicin. Acta Oncol 33: 779-786.
27. Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, et al. (1994) Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 54: 987-992.
28. Baert L, van't Klooster G, Dries W, Francois M, Wouters A, et al. (2009) Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment. Eur J Pharm Biopharm 72: 502-508.
29. Dou H, Grotepas CB, McMillan JM, Destache CJ, Chaubal M, et al. (2009) Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS. J Immunol 183: 661-669.
30. Garg M, Asthana A, Agashe HB, Agrawal GP, Jain NK, (2006) Stavudine-loaded mannosylated liposomes: in-vitro anti-HIV-I activity, tissue distribution and pharmacokinetics. J Pharm Pharmacol 58: 605-616.
31. Kaur CD, Nahar M, Jain NK, (2008) Lymphatic targeting of zidovudine using surface-engineered liposomes. J Drug Target 16: 798-805.
32. Dutta T, Agashe HB, Garg M, Balakrishnan P, Kabra M, et al. (2007) Poly (propyleneimine) dendrimer based nanocontainers for targeting of efavirenz to human monocytes/macrophages in vitro. J Drug Target 15: 89-98.
33. Dutta T, Garg M, Jain NK, (2008) Targeting of efavirenz loaded tuftsin conjugated poly(propyleneimine) dendrimers to HIV infected macrophages in vitro. Eur J Pharm Sci 34: 181-189.
34. Jordan A, Bisgrove D, Verdin E, (2003) HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. Embo J 22: 1868-1877.
35. Pollock S, Dwek RA, Burton DR, Zitzmann N, (2008) N-Butyldeoxynojirimycin is a broadly effective anti-HIV therapy significantly enhanced by targeted liposome delivery. Aids 22: 1961-1969.
36. Reuse S, Calao M, Kabeya K, Guiguen A, Gatot JS, et al. (2009) Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PLoS One 4: e6093.
37. Brooks DG, Hamer DH, Arlen PA, Gao L, Bristol G, et al. (2003) Molecular characterization, reactivation, and depletion of latent HIV. Immunity 19: 413-423.
38. Brooks DG, Arlen PA, Gao L, Kitchen CM, Zack JA, (2003) Identification of T cell-signaling pathways that stimulate latent HIV in primary cells. Proc Natl Acad Sci U S A 100: 12955-12960.
39. Brooks DG, Kitchen SG, Kitchen CM, Scripture-Adams DD, Zack JA, (2001) Generation of HIV latency during thymopoiesis. Nat Med 7: 459-464.
40. Arlen PA, Brooks DG, Gao LY, Vatakis D, Brown HJ, et al. (2006) Rapid expression of human immunodeficiency virus following activation of latently infected cells. J Virol 80: 1599-1603.
41. Korin YD, Brooks DG, Brown S, Korotzer A, Zack JA, (2002) Effects of prostratin on T-cell activation and human immunodeficiency virus latency. J Virol 76: 8118-8123.
42. Brooks DG, Zack JA, (2002) Effect of latent human immunodeficiency virus infection on cell surface phenotype. J Virol 76: 1673-1681.
43. Desormeaux A, Bergeron MG, (2005) Lymphoid tissue targeting of anti-HIV drugs using liposomes. Methods Enzymol 391: 330-351.
44. Gagne JF, Desormeaux A, Perron S, Tremblay MJ, Bergeron MG, (2002) Targeted delivery of indinavir to HIV-1 primary reservoirs with immunoliposomes. Biochim Biophys Acta 1558: 198-210.
45. Oussoren C, Storm G, (2001) Liposomes to target the lymphatics by subcutaneous administration. Adv Drug Deliv Rev 50: 143-156.
46. Cagdas FM, Ertugral N, Bucak S, Atay NZ, Effect of preparation method and cholesterol on drug encapsulation studies by phospholipid liposomes. Pharm Dev Technol.
47. Hansen CB, Kao GY, Moase EH, Zalipsky S, Allen TM, (1995) Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures. Biochim Biophys Acta 1239: 133-144.
48. Jones HW Jr, McKusick VA, Harper PS, Wuu KD, (1971) George Otto Gey. (1899-1970). The HeLa cell and a reappraisal of its origin. Obstet Gynecol 38: 945-949.
49. Foley GE, Lazarus H, Farber S, Uzman BG, Boone BA, et al. (1965) Continuous Culture of Human Lymphoblasts from Peripheral Blood of a Child with Acute Leukemia. Cancer 18: 522-529.